title: Impact of Pelvic and Para-aortic Lymphadenectomy in Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
abstract: OBJECTIVE
  The aim of our study was to evaluate the impact of systemic pelvic and para-aortic lymphadenectomy on survival in patients with advanced ovarian cancer after neoadjuvant chemotherapy.
  
  
  METHODS
  This multi-centric descriptive study included patients with initially inoperable advanced ovarian cancer, undergoing neoadjuvant chemotherapy followed by cytoreductive surgery with no residual tumor between 1998 and 2012. They were distributed into two groups depending on if they underwent lymphadenectomy or not during the interval surgery.
  
  
  RESULTS
  Among the 101 included patients, 54 underwent lymphadenectomy and 47 did not. The multivariate analysis for overall survival showed no significant difference between the two groups [hazard ratio (HR)=1.88, confidence interval (CI)=0.89-3.94; p=0.08]. The multivariate analysis for progression-free survival showed no significant difference (HR=1.43, 95% CI=0.86-2.39; p=0.17).
  
  
  CONCLUSIONS
  In patients with advanced ovarian cancer, treated by neoadjuvant chemotherapy and interval surgery with no residual tumor, lymphadenectomy does not seem to improve the survival rate.
authors.affiliation: Department of Gynecology and Obstetrics, Hautepierre Hospital, University Hospital of Strasbourg, Strasbourg, France schwartz.lu@gmail.com.
authors.forename: Lucie
authors.initials: L
authors.lastname: Schwartz
authors.affiliation: Department of Gynecology and Obstetrics, Hautepierre Hospital, University Hospital of Strasbourg, Strasbourg, France.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Schrot-Sanyan
authors.affiliation: Department of General and Digestive Surgery, Hautepierre Hospital, University Hospital of Strasbourg, Strasbourg, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Brigand
authors.affiliation: Department of Gynecology and Obstetrics, Hautepierre Hospital, University Hospital of Strasbourg, Strasbourg, France.
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Baldauf
authors.affiliation: Department of Gynecology and Obstetrics, Hautepierre Hospital, University Hospital of Strasbourg, Strasbourg, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Wattiez
authors.affiliation: Department of Gynecology and Obstetrics, Hautepierre Hospital, University Hospital of Strasbourg, Strasbourg, France.
authors.forename: Cherif
authors.initials: C
authors.lastname: Akladios
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000401:mortality*; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D010220:Para-Aortic Bodies / Q000473:pathology*; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D015996:Survival Rate
keywords: Ovarian cancer; lymphadenectomy; neoadjuvant chemotherapy; overall surivival